Anti-aging skin therapy in perimenopausal and postmenopausal women Skin and Connective Tissue Diseases
Conditions
Interventions
The intervention will consist of two stages. The trial participants will be 46 perimenopausal and 46 postmenopausal women. Participants will be qualified for the trial by a cosmetic dermatologist and
Sponsors
The Academy of Physical Education in Katowice
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Current inclusion criteria as of 03/01/2023: 1st stage of intervention participant inclusion criteria: 1. Age of 40-58 years and menstruation for the group of perimenopausal women 2. Patient consent for the trial 3. Fitzpatrick skin type 2-3 4. Contraindications for chemical exfoliation (bacterial, viral or fungal infections, other inflammatory dermatoses such as psoriasis and topical dermatitis, topical retinoids treatment, keloid and scarring tendency) 5. No previous treatments of TCA chemical peels 6. No previous exfoliating and rejuvenating treatments within the previous 6 months, including chemical peels, microneedle radiofrequency, fractional ablation laser, microneedling therapy etc 2nd stage of intervention participant inclusion criteria: 1. Age 59-65 years for postmenopausal women 2. Patient consent for the trial 3. Fitzpatrick skin type 2-3 4. Contraindications for chemical exfoliation (bacterial, viral or fungal infections, other inflammatory dermatoses such as psoriasis and topical dermatitis, topical retinoids treatment, keloid and scarring tendency) 5. No previous treatments of TCA chemical peels 6. No previous exfoliating and rejuvenating treatments within the previous 6 months, including chemical peels, microneedle radiofrequency, fractional ablation laser, microneedling therapy etc _____ Previous inclusion criteria: 1st stage of intervention participant inclusion criteria: 1. Age of 40-58 years and menstruation for the group of perimenopausal women 2. Patient consent for the trial 3. Fitzpatrick skin type 2-3 4. Contraindications for chemical exfoliation (bacterial, viral or fungal infections, other inflammatory dermatoses such as psoriasis and topical dermatitis, topical retinoids treatment, keloid and scarring tendency) 5. No previous treatments of TCA chemical peels 6. No previous exfoliating and rejuvenating treatments within the previous 6 weeks, including chemical peels, microneedle radiofrequency, fractional ablation laser, microneedling therapy etc 2nd stage of intervention participant inclusion criteria: 1. Age 59-65 years for postmenopausal women 2. Patient consent for the trial 3. Fitzpatrick skin type 2-3 4. Contraindications for chemical exfoliation (bacterial, viral or fungal infections, other inflammatory dermatoses such as psoriasis and topical dermatitis, topical retinoids treatment, keloid and scarring tendency) 5. No previous treatments of TCA chemical peels 6. No previous exfoliating and rejuvenating treatments within the previous 6 weeks, including chemical peels, microneedle radiofrequency, fractional ablation laser, microneedling therapy etc
Exclusion criteria
Exclusion criteria: Participant exclusion criteria (the same for the two experimental and control groups): 1. Contraindications to chemical exfoliation (local infections etc) 2. Malignancy 3. Pregnancy and breastfeeding 4. No possibility to participate in follow-up visits 5. History of mental illness and unrealistic expectations about the results of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Skin hydration measured by Corneometer® MC750 B2 (Courage + Khazaka Electronic GmbH, Cologne, Germany) at baseline, 1 month and 3 months after treatment. 2. Skin elasticity measured by Cutometer® MC750 B2 (Courage + Khazaka Electronic GmbH, Cologne, Germany) at baseline, 1 month and 3 months after treatment 3. Wrinkle appearance measured by series of photos with the Canon EOS60D camera at baseline, 1 month and 3 months after treatment. 5. Wrinkle appearance measured by series of photos with the Fujifilm XT1 camera at baseline, 1 month and 3 months after treatment. 6. Wrinkle appearance measured by series of photos with the DUB SkinScanner 75 at baseline, 1 month and 3 months after treatment. 7. Wrinkle appearance measured by series of photos with the Artec Leo Easy 3D scanner at baseline, 1 month and 3 months after treatment. 8. Wrinkle appearance measured by series of photos with the Firely DE300 Digital Video Dermatoscope at baseline, 1 month and 3 months after treatment. 9. Wrinkle appearance measured by series of photos with the Wrinkle Severity Rating Scale at baseline, 1 month and 3 months after treatment. 10. Skin discoloration and redness measured by Mexameter® MC750 B2 (Courage + Khazaka Electronic GmbH, Cologne, Germany) at baseline, 1 month and 3 months after treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Skin sebum secretion measured by Sebumeter® MC750 B2 (Courage + Khazaka Electronic GmbH, Cologne, Germany) at baseline, 1 month and 3 months after treatment. 2. Skin aesthetic improvement measured by the Patient's Aesthetic Improvement Scale (PAIS) at baseline, 1 month and 3 months after treatment. 3. Skin aesthetic improvement measured by the Global Aesthetic Improvement Scale (GAIS) at baseline, 1 month and 3 months after treatment. 4. Skin aesthetic improvement measured by the Artec Leo Easy 3D scanner at baseline, 1 month and 3 months after treatment. 5. Skin aesthetic improvement measured by the DUB SkinScanner 75 at baseline, 1 month and 3 months after treatment. | — |
Countries
Poland
Outcome results
None listed